Comparative Study of the Efficacy and Safety of Ambervin and Standard Therapy in Hospitalized Patients With COVID-19
Status:
Completed
Trial end date:
2022-11-22
Target enrollment:
Participant gender:
Summary
This is open-labe randomized multicenter comparative Phase III study conducted in 8 medical
facilities. The objective of the study is to assess the efficacy, safety and tolerability of
Ambervin for intramuscular and inhaled administration in complex therapy COVID-19 compared
with the Standard of care (SOC) in hospitalized patients with moderate COVID-19.